

21 January 2020

Australian Securities Exchange
20 Bridge Street
Sydney NSW 2000

Change to Managing Director's Remuneration Package

Melbourne, Victoria – Alcidion Group Ltd (ASX:ALC) today advises changes to the remuneration package of the Company's Managing Director, Ms Kate Quirke.

Following a review by the Company's Remuneration and Nomination Committee, in conjunction with an independent remuneration consultant, the Board has advised that Ms Quirke's remuneration package has been updated to reflect industry benchmarks.

Alcidion Chair Rebecca Wilson said, "In her tenure as CEO and Managing Director of Alcidion, Kate has demonstrated her ability to grow the business and deliver a meaningful uplift in revenue.

"This updated remuneration package is in-line with industry benchmarks and is aligned with shareholder interests. The package appropriately recognises Kate for her achievements to date while incentivising her to strive for further growth."

In accordance with ASX Listing Rule 3.16.4, the new terms of Ms Quirke's remuneration package are as follows:

Title	Managing Director
Effective Date	1 January 2020
Amended Base Remuneration	\$413,461 gross inclusive of statutory superannuation, any allowances and salary sacrifices.
Incentives	STI available of \$96,000 on achieving on-budget revenue and other personal performance targets with up to an additional \$64,000 on achieving stretch targets. Eligibility to participate in the Long Term Incentive Plan (LTIP) with the issue of rights or options (subject to shareholder approval) up to the value of 100% of base salary, vesting after 3 years. Terms and hurdles of the LTIP are to be determined in Q1 2020.
Notice period for termination	6 months' notice (except where immediate termination is permitted)

ENDS

For further information, please contact:

KYAHN WILLIAMSON

WE Communications

Ph: 0401018828

kwilliamson@we-buchan.com

About Alcidion

Alcidion Group Limited (ASX:ALC) has a simple purpose: to transform healthcare with smart, intuitive technology solutions that meet the needs of hospital and allied healthcare, worldwide. It offers a complementary set of software products and services that create a unique offering in the global healthcare market; solutions that support interoperability, allow communication and task management and deliver clinical decision support at the point of care to improve patient outcomes. In 2017, Alcidion acquired Oncall Systems and its Smartpage clinical communication system. In 2018, it acquired the Patientrack bedside patient monitoring software and MKM Health, an IT solutions and services provider. These offerings now operate under the Alcidion brand. With over 25 years of combined healthcare experience, Alcidion brings together the very best in technology and market knowledge to deliver solutions that make healthcare better for everyone.

www.alcidion.com

© Alcidion Group Limited 2020. Alcidion, MKM Health, Miya, Patientrack and Smartpage are registered trademarks. All other brands and product names and trademarks are the registered property of their respective companies.

This announcement is authorised for release by the Board of Directors of Alcidion Limited.

For personal use only